Arbor Emphasizes Risks Of Its Own Product In Suit Against US FDA To Block Nymalize Generics
Executive Summary
FDA concluded that original formulation of brain hemorrhage treatment was not discontinued for safety or effectiveness reasons, saying Arbor had other options to reduce risk of confusion between the new and original formulations. But the sponsor argues that withdrawal was part of FDA-approved risk mitigation plan.
You may also be interested in...
New Nimodipine Formulation Aimed At Reducing Fatal Medication Errors
Nymalize, an oral formulation of brain hemorrhage treatment nimodipine, aims to minimize serious risks associated with incorrect administration of older forms of the drug.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.